About clonoSEQ

A test that’s as wise as today’s cancer treatments

clonoSEQ is a blood or bone marrow test1 that measures your cancer at the deepest level currently available1-3, helping your doctor make more informed decisions about your care. It is FDA-cleared and CLIA-validated in bone marrow and peripheral blood for chronic lymphocytic leukemia (CLL).

clonoSEQ is a blood or bone marrow test1 that measures your cancer at the deepest level currently available1-3, helping your doctor make more informed decisions about your care. It is FDA-cleared and CLIA-validated in bone marrow and peripheral blood for chronic lymphocytic leukemia (CLL).

clonoSEQ is covered by Medicare and other major insurance providers

— Lee, CLL patient who tested with clonoSEQ

What does 1 in a million mean to you? It means that you and your doctor know exactly where you are on your blood cancer journey. And when it comes to cancer, knowledge is power. By precisely tracking MRD both during and after treatment, you and your doctor can be more informed about your response to therapy—and can plan next steps accordingly.

*If sufficient sample material is provided.

clonoSEQ can identify residual disease that other tests miss4

Your doctor will likely order other tests—like flow tests or routine blood work—to
monitor your cancer. This is a good thing! It means your doctor is trying to gather as much useful information as possible. To best understand how your cancer may be changing over time, these tests can be paired with a highly sensitive MRD testing tool like clonoSEQ.

clonoSEQ detected MRD in

of patients who were deemed
MRD-negative by a flow test4

Here are some questions to help you start a conversation with your doctor.

  • Is MRD testing with clonoSEQ right for me?
  • I heard that clonoSEQ can identify 1 cancer cell out of a million cells with sufficient sample provided. Why does that matter for me?
  • What can MRD testing with clonoSEQ tell me about my cancer?
  • How will you incorporate my MRD results with clonoSEQ into my treatment plan?
  • At what points during the treatment process should I have a clonoSEQ MRD test?
  • Is clonoSEQ testing covered by insurance?

This page is intended for a US-based audience.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.

References:

  1. clonoSEQ®. [technical summary]. Seattle, WA: Adaptive Biotechnologies; 2020.
  2. Short NJ, et al. Am J Hematol. 2019;94:257-265.
  3. Martinez-Lopez J, et al. J Hematol Oncol. 2021;14(1):126.
  4. Data on file. Adaptive Biotechnologies. 2020.
  5. Al-Sawaf O, et al. ASH 2020. Abstract 127.
  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia V.4. 2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed January 16, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.